Payer Management Tool

UnitedHealth-Mayo: More Data, More Open. But Not Quite Neutral

Posted by on Jan 22, 2013 in Affordable Care Act, Cost/Comparative Effectiveness, Payer Management Tool, Payers: Commercial, Payers: Managed Medicaid/Medicare, Payment Reform, Pharmaceuticals, Physician practice patterns, Pricing

UnitedHealth’s outcomes-focused research alliance with Mayo Clinic, announced Jan. 15, reminds us of big data’s central role in creating a value-driven US health care system.  The tie-up claims to have...

Learn More

Reimbursement “Furies” Real, But Won’t Avenge Pharma Til 2017, Says Citi

Posted by on Dec 4, 2012 in Adherence, Company, Cost/Comparative Effectiveness, Diagnostics, Health Technology Assessments, Medical Innovation, Payer Management Tool, Payers: Commercial, Payers: Managed Medicaid/Medicare, Payment Reform, Pharmaceuticals, Pricing

“Beware the Three Furies,” warns Citi analyst Andrew Baum.  In a report for pharma investors published Nov. 29., Baum turns to classical mythology to describe shared savings models, drug pathways...

Learn More

Sanofi Blinks First: Zaltrap Price Cut Proves HTA Has Reached The US

Posted by on Nov 12, 2012 in Company, Cost/Comparative Effectiveness, Health Technology Assessments, Medical Innovation, Payer Management Tool, Payers: Commercial, Payers: Managed Medicaid/Medicare, Payment Reform, Pharmaceuticals, Pricing, Product Launch, Value-based pricing

Sanofi’s decision last week to cut the price of its colon cancer drug Zaltrap by up to 50% showed that the US market is no longer immune to European-style drug price pressure. Never mind that the move...

Learn More

Risk-Shares Pop Up Again As Payers, Pharma Circle New Payment Models

Posted by on Oct 3, 2012 in Company, Cost/Comparative Effectiveness, Health Technology Assessments, Medical Innovation, Payer Management Tool, Payers: Commercial, Payment Reform, Pharmaceuticals, Physician practice patterns, Pricing, Product Launch, Value-based pricing

Say you’re GSK, and a head-to-head trial pitting your drug against the market leader showed non-inferiority. Say, too, that even though you assembled some trial evidence that patients preferred your drug vs....

Learn More

The Big-Data Race Is On. But Real World Evidence Won’t Solve Pharma’s Trust Problem

Posted by on Sep 27, 2012 in Cost/Comparative Effectiveness, Health Technology Assessments, Payer Management Tool, Payers: Commercial, Payers: Managed Medicaid/Medicare, Pharmaceuticals

As payers step up their hunt for drugs’ ‘value’ – defined, in their eyes, in terms of outcomes — so pharma is scrambling for real world data that can prove how well their products work in practice....

Learn More